Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/103382
Title: Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
Author: Triulzi, Tiziana
De Cecco, Loris
Sandri, Marco
Prat Aparicio, Aleix
Giussani, Marta
Paolini, Biagio
Carcangiu, Maria Luisa
Canevari, Silvana
Bottini, Alberto
Balsari, Andrea
Menard, Sylvie
Generali, Daniele
Campiglio, Manuela
Di Cosimo, Serena
Tagliabue, Elda
Keywords: Càncer de mama
Expressió gènica
Limfòcits
Terapèutica
Anticossos monoclonals
Breast cancer
Gene expression
Lymphocytes
Therapeutics
Monoclonal antibodies
Issue Date: 29-Sep-2015
Publisher: Impact Journals
Abstract: While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinomas obtained from patients treated with trastuzumab-containing therapies and correlated the molecular portrait with treatment benefit. The estimated association between gene expression and relapse-free survival allowed development of a trastuzumab risk model (TRAR), with ERBB2 and ESR1 expression as core elements, able to identify patients with high and low risk of relapse. Application of the TRAR model to 24 HER2+ core biopsies from patients treated with neo-adjuvant trastuzumab indicated that it is predictive of trastuzumab response. Examination of TRAR in available whole-transcriptome datasets indicated that this model stratifies patients according to response to trastuzumab-based neo-adjuvant treatment but not to chemotherapy alone. Pathway analysis revealed that TRAR-low tumors expressed genes of the immune response, with higher numbers of CD8-positive cells detected immunohistochemically compared to TRAR-high tumors. The TRAR model identifies tumors that benefit from trastuzumab-based treatment as those most enriched in CD8-positive immune infiltrating cells and with high ERBB2 and low ESR1 mRNA levels, indicating the requirement for both features in achieving trastuzumab response.
Note: Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.4405
It is part of: Oncotarget, 2015, vol. 6, num. 29, p. 28173-28182
Related resource: https://doi.org/10.18632/oncotarget.4405
URI: http://hdl.handle.net/2445/103382
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
662488.pdf3.35 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons